Volpara

Volpara Health breast density and mammography quality software highlighted in new peer-reviewed research

Retrieved on: 
Wednesday, December 20, 2023
ASX, Mammography, Breast cancer, Software, Physics, Research, Patient safety, Cancer, 3D, Volpara, Radiation, Joint, Medical physics, Patient, VBD, 2D, Analytics, Algorithm, RSNA, Medical imaging

LYNNWOOD, Wash., Dec. 20, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, was featured in two peer reviewed studies published during this year's Radiological Society of North America (RSNA) annual meeting.

Key Points: 
  • The report, "Breast dosimetry for standard and contrast-enhanced mammography and breast tomosynthesis," advocates for international harmonization of mammography dose estimates, by implementation of the new and improved model and methodology.
  • Featured in European Radiology , a second peer-reviewed study investigates whether active use of Volpara Analytics ® software could help breast radiographers to improve their screening image quality.
  • By empowering clinicians with innovative tools, Volpara exemplifies its commitment to advancing mammography quality and the early detection of breast cancer," said Melissa Hill, Volpara Health Senior Imaging Scientist and Global Research Lead.
  • Volpara strives for continuous advancements in AI for breast care, which aligns with the company's mission to save more families from cancer.

Lunit to Acquire Volpara: Scheme Implementation Agreement Signed

Retrieved on: 
Thursday, December 14, 2023
Acquisition, Organization, Chicken (Scheme implementation), Patient, USD, Therapy, Radiology, Cancer, High court, Growth, AI, Knowledge, Property management, Medical device, Management, Volpara, Scheme

SEOUL. South Korea, Dec. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced its proposal to acquire Volpara Health Technologies Ltd. (Volpara; ASX:VHT), a global leader in AI-enabled software for the early detection and prevention of cancer. The strategic move comes as a result of an exhaustive evaluation of potential avenues for growth and innovation by Lunit.

Key Points: 
  • The strategic move comes as a result of an exhaustive evaluation of potential avenues for growth and innovation by Lunit.
  • Following the decision, Lunit and Volpara have entered into a Scheme Implementation Agreement, under which Lunit will acquire all of Volpara's shares at a price of AUD 1.15 per share through a New Zealand scheme of arrangement (Scheme).
  • Volpara's AI-powered mammography solutions, operational in over 2,000 U.S. medical sites, would catapult Lunit into the forefront of the American market," said Brandon Suh, CEO of Lunit.
  • The Scheme is contingent upon Volpara shareholders' and New Zealand High Court's approval, regulatory clearances from the New Zealand Overseas Investment Office, and fulfillment of other customary conditions outlined in the Scheme Implementation Agreement.

Volpara Health enters agreement to be acquired by Lunit, Inc.

Retrieved on: 
Wednesday, December 13, 2023
Radiology, Cancer, Breast cancer, Software, Volpara

WELLINGTON, New Zealand, Dec. 13, 2023 /PRNewswire/ -- Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX:VHT), a global leader in software for the early detection of breast cancer, is pleased to announce it has entered into an agreement to be acquired by Lunit Inc.

Key Points: 
  • WELLINGTON, New Zealand, Dec. 13, 2023 /PRNewswire/ -- Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX:VHT), a global leader in software for the early detection of breast cancer, is pleased to announce it has entered into an agreement to be acquired by Lunit Inc.
  • The transaction is expected to accelerate Volpara's ability to serve its purpose of saving families from cancer.
  • Working together, Lunit and Volpara would have the opportunity to develop products that very few companies are in a position to do.
  • Volpara shareholders will have the opportunity to vote on the proposed Scheme at a meeting in early Q2 2024.

Volpara Health and LehYup Partner on Cancer Risk Assessment Services at RSNA 2023

Retrieved on: 
Monday, November 27, 2023
Well, RSNA, Data management, EHR, Volpara, Nursing, Risk, Patient, Medicine, ASX, Genetic testing, Risk assessment, Cancer, Software, Partnership, Population health, Health care, Physician, Empathy, Health

CHICAGO, Nov. 27, 2023 /PRNewswire/ -- Experienced cancer risk assessment program experts from Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, will be joined by a new technical partner LehYup LLC at the Annual Radiological Society of North America (RSNA) meeting, November 26-29, 2023 (South Hall, Booth #2780).

Key Points: 
  • CHICAGO, Nov. 27, 2023 /PRNewswire/ -- Experienced cancer risk assessment program experts from Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, will be joined by a new technical partner LehYup LLC at the Annual Radiological Society of North America (RSNA) meeting, November 26-29, 2023 (South Hall, Booth #2780).
  • LehYup LLC, an IT integration and optimization firm, will work alongside Volpara's professional services and deployment staff by providing advanced Epic® build skills to maximize cancer screening and prevention programs.
  • Volpara's Risk Pathways® is market-leading breast cancer risk assessment software, which is currently used by more than 1,000 providers across the United States to perform more than 3 million risk assessments every year.
  • This comprehensive cancer risk assessment software helps clinicians make better informed decisions for triaging patients to supplemental imaging and/or genetic testing based on their individual risk profile.

Volpara Health ushers in new era of breast imaging at RSNA 2023

Retrieved on: 
Wednesday, November 22, 2023
Breast, RSNA, Woman, EHR, Research, Patient, Risk, Artificial intelligence, Cohort (statistics), Mammography, Peter Hancock (professor), Algorithm, Kettering Health, ASX, Artificiality, Accreditation, EQUIP, Genetic testing, Automation, Risk assessment, Software, Cancer, Health care, MRI, AI, ACR, Microsoft, Neoplasm, Overalls, Health, Medical device, Medical imaging, Volpara, Radiology

CHICAGO, Nov. 22, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, will showcase its latest software advancements at the Annual Radiological Society of North America (RSNA) meeting, November 26-29, 2023 (South Hall, Booth #2780).

Key Points: 
  • This comprehensive cancer risk assessment software capitalizes on the opportunity of mammography and wellness appointments to personalize care.
  • The Volpara AI-powered solutions on display at RSNA excel at automating manual, time-consuming and subjective tasks to help providers and patients thrive in this new era."
  • The Elizabeth Wende Breast Center will report on the outcomes of five years of high-risk screening with supplemental MRI and genetic testing.
  • The scientific poster shows that using Volpara Risk Pathways and Volpara density assessment software can lead to better outcomes through implementing risk assessment in a large community-based program.

Volpara Health partners with Trees that Count to offset carbon emissions

Retrieved on: 
Wednesday, July 26, 2023
Tree, Electricity, DNA, Cancer, ASX, Bird, Carbon, Software, Agriculture, Volpara

LYNNWOOD, Wash., July 26, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection of cancer, has made a new commitment to offset more carbon emissions by partnering with Trees that Count. This environmental charity brings together business, community, and everyday New Zealand residents to plant millions of trees across the country.

Key Points: 
  • LYNNWOOD, Wash., July 26, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection of cancer, has made a new commitment to offset more carbon emissions by partnering with Trees that Count.
  • This environmental charity brings together business, community, and everyday New Zealand residents to plant millions of trees across the country.
  • Volpara has already reduced its carbon emissions by 17.4% this year.
  • "Volpara believes that every company can do something to help reduce emissions, and I am delighted that our trees will help protect native birds in New Zealand," said Kathryn Greene, Chief People Office at Volpara.

Volpara recognized as the winner of 2023 Microsoft Healthcare & Life Sciences Partner of the Year

Retrieved on: 
Tuesday, June 27, 2023
Cloud, Microsoft, Inspiration, Software as a service, Ernst & Young Entrepreneur of the Year Award, Microsoft Azure, Microsoft Security Essentials, Cardiovascular disease, Life, Cancer, ASX, Software, BAC, US, Machine learning, Corporation, Azure, ISV, Health, Mammography, Breast cancer, Video game, Health care, Volpara

SEATTLE, June 27, 2023 /PRNewswire/ -- Volpara Health (ASX: VHT), a global leader in software for the early detection of breast cancer, today announced it has won the Healthcare & Life Sciences 2023 Microsoft Partner of the Year Award.

Key Points: 
  • SEATTLE, June 27, 2023 /PRNewswire/ -- Volpara Health (ASX: VHT), a global leader in software for the early detection of breast cancer, today announced it has won the Healthcare & Life Sciences 2023 Microsoft Partner of the Year Award.
  • Of the awards, Teri Thomas, Volpara CEO and Managing Director, said: "We love our Microsoft partners and are so proud to be named Microsoft Partner of the Year in the Healthcare & Life Sciences category.
  • Volpara was recognized for providing outstanding solutions and services in Healthcare & Life Sciences.
  • The Healthcare & Life Sciences Partner of the Year Award recognizes a partner organization that excels at providing innovative healthcare and life sciences services or solutions based on Microsoft cloud technologies, driving customer growth, transformation, and enhanced patient care.

Volpara Health Joins CancerX

Retrieved on: 
Friday, June 2, 2023
White House, Communication, Partnership, Life, Yale Physician Associate Program, Policy, American Society of Clinical Oncology, Cancer, ASX, VHT, Volpara, Cancer Moonshot, Incidence, Multi, Health, Society, Dime, Pharmaceutical industry

LYNNWOOD, Wash., June 2, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT) proudly announces its founding membership in CancerX, a public-private partnership aimed at revolutionizing cancer innovation in the United States. As a global leader in cancer detection software, Volpara joins other leaders in advancing patient care, communication, and policy in the fight against this devastating disease.

Key Points: 
  • LYNNWOOD, Wash., June 2, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT) proudly announces its founding membership in CancerX , a public-private partnership aimed at revolutionizing cancer innovation in the United States.
  • As a global leader in cancer detection software, Volpara joins other leaders in advancing patient care, communication, and policy in the fight against this devastating disease.
  • Andrea Wolf, Public Policy Advisor, Volpara Health, states, "Cancer Moonshot success requires deep collaboration, novel approaches, and focused direction.
  • "Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we're honored to partner with Volpara Health to achieve the ambitious goals of CancerX," said Smit Patel, Associate Program Director at DiMe.

Artificial Intelligence from ScreenPoint Medical and Volpara Health Demonstrates Ability to Predict Long-Term Breast Cancer Risk

Retrieved on: 
Tuesday, May 23, 2023
Risk, Mayo Clinic, University, Breast cancer screening, American Journal of Clinical Oncology, Workflow, Breast cancer awareness, Radiology, Cancer, Risk assessment, Woman, University of California, Research, Doctor of Philosophy, Density, Volpara, Breast, Radboud University Nijmegen, Journal, Machine learning, Algorithm, Interval, Artificial Intelligence System, Workload, Physics, Artificial intelligence, AI, Clinical professor, Information Innovation Office, Breast cancer, Medical imaging

NIJMEGEN, Netherlands and WELLINGTON, New Zealand, May 23, 2023 /PRNewswire/ -- Researchers from the Mayo Clinic (Rochester, MN) and University of California, San Francisco confirmed that pairing artificial intelligence (AI) imaging and volumetric breast density algorithms can assist in predicting long-term risk of breast cancer, in particular invasive disease. The study, "Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer," was recently published in the Journal of Clinical Oncology.

Key Points: 
  • The study, " Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer ," was recently published in the Journal of Clinical Oncology.
  • Researchers used images from 2,412 women with invasive breast cancer and 4,995 matched controls who had digital mammograms performed 2-5.5 years before cancer diagnosis.
  • Transpara AI score improves long-term risk prediction when combined with clinical risk factors including breast density for overall invasive cancers, screen-detected, advanced, and nonadvanced cancers.
  • ScreenPoint Medical translates cutting edge machine learning research into technology accessible by radiologists to improve screening workflow, decision confidence and breast cancer risk assessment.

Artificial Intelligence from ScreenPoint Medical and Volpara Health Demonstrates Ability to Predict Long-Term Breast Cancer Risk

Retrieved on: 
Tuesday, May 23, 2023
Risk, Mayo Clinic, University, Breast cancer screening, American Journal of Clinical Oncology, Workflow, Breast cancer awareness, Radiology, Cancer, Risk assessment, Woman, University of California, Research, Doctor of Philosophy, Density, Volpara, Breast, Radboud University Nijmegen, Journal, Machine learning, Algorithm, Interval, Artificial Intelligence System, Workload, Physics, Artificial intelligence, AI, Clinical professor, Information Innovation Office, Breast cancer, Medical imaging

NIJMEGEN, Netherlands and WELLINGTON, New Zealand, May 23, 2023 /PRNewswire/ -- Researchers from the Mayo Clinic (Rochester, MN) and University of California, San Francisco confirmed that pairing artificial intelligence (AI) imaging and volumetric breast density algorithms can assist in predicting long-term risk of breast cancer, in particular invasive disease. The study, "Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer," was recently published in the Journal of Clinical Oncology.

Key Points: 
  • The study, " Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer ," was recently published in the Journal of Clinical Oncology.
  • Researchers used images from 2,412 women with invasive breast cancer and 4,995 matched controls who had digital mammograms performed 2-5.5 years before cancer diagnosis.
  • Transpara AI score improves long-term risk prediction when combined with clinical risk factors including breast density for overall invasive cancers, screen-detected, advanced, and nonadvanced cancers.
  • ScreenPoint Medical translates cutting edge machine learning research into technology accessible by radiologists to improve screening workflow, decision confidence and breast cancer risk assessment.